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Abstract 
The recently reported results of Lu et al. (Theranostics. 2018; 8: 1312-26. doi:10.7150/thno.21745) 
– highlighting GLUT1 expression as a marker for sensitivity of gastric cancer cells to therapeutic 
doses of ascorbate – are discussed in the light of additional factors potentially affecting the 
underlying processes, such as the concomitant expression of membrane gamma-glutamyltransferase 
activity, the resistance of cancer cells to oxidative injury and other known biomarkers. 
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Introduction 
Ascorbic acid (AA) has been proposed as an 
anticancer treatment during several decades, since the 
seminal observation by Cameron & Pauling that 
supplementation of the vitamin would often allow a 
remarkable prolongation of survival of terminal 
cancer patients [1]. Numerous studies have been 
published to date largely confirming the beneficial 
action of high dose ascorbate, alone or in association 
with other micronutrients, or as a means to sensitize 
cancer cells to the effects of other recognized 
genotoxic chemotherapeutics.  
It was originally thought that AA might be 
involved in host resistance to expansion of the disease 
as it would support collagen biosynthesis, thus 
helping maintain the resistance of the ground 
substance to malignant invasive growth [2]. On the 
other hand, with the exploration of biochemical 
mechanisms underlying the phenomenon it has 
become increasingly clear that cytostatic/cytotoxic 
effects of ascorbate are prevailing, and are correlated 
with prooxidant reactions. The prooxidant activity of 
AA is well known, and in selected conditions can 
predominate over its antioxidant properties [3, 4]. In 
particular, it has been documented that AA can give 
rise to increased steady-state levels of reactive oxygen 
species (ROS), including superoxide and hydrogen 
peroxide, which can produce an increase in the 
redox-active labile iron pool of cancer cells. Iron 
metabolism is in fact often altered in cancer cells, with 
upregulation of iron uptake and downregulation of 
export and storage pathways. The cytotoxic effect of 
AA can be thus explained as the result of 
iron-dependent prooxidant damage involving cell 
membranes, mitochondria and DNA [5, 6]. 
GLUT1 expression as a marker of 
sensitivity to AA 
A recent article by Lu et al. in this Journal 
confirmed the therapeutic potential of high-dose 
ascorbate, and added further intriguing insights [7]. 
The authors demonstrated that gastric cancer cells 
with high GLUT1 expression were more sensitive to 
ascorbate treatment than cells with low GLUT1 









glutathione, generate oxidative stress and induce 
DNA damage. The combination of pharmacological 
AA with genotoxic agents (oxaliplatin, irinotecan) 
was also investigated, showing a synergistical 
inhibition of tumor growth in vivo. GLUT1 expression 
may serve thus as a marker for sensitivity of gastric 
cancer cells to AA treatments. 
Extracellular AA oxidation: the role of 
gamma-glutamyltransferase 
One critical aspect of the matter however was 
not discussed, i.e., the fact that facilitation of ascorbate 
uptake by cells through the glucose transporter 
protein, GLUT1 (as well as GLUT3) can only occur 
after extracellular AA is oxidized to dehydroascorbic 
acid (DHA: a molecule structurally similar to 
glucose). Once within cells, DHA is then immediately 
reduced to AA by both chemical and protein 
mediated processes [8]. Indeed, it was shown that 
tumor cells can spontaneousy obtain vitamin C from 
the medium by inducing the oxidation of AA to DHA, 
and such oxidation was ascribed to NADPH oxidase 
activities present in non-malignant stromal cells (e.g. 
phagocytes, fibroblasts, endothelial cells) [9]. An 
endogenous production of ROS has been observed in 
several cancer cell types including melanoma, where 
it likely ensues from prooxidant reactions taking place 
during melanogenesis [10]. On the other hand, studies 
performed in our own laboratories allowed to 
describe another, potentially crucial source of 
prooxidants capable of oxidizing AA to DHA at the 
surface of cancer cells, i.e. membrane 
gamma-glutamyltransferase (GGT) activity. We have 
documented that membrane GGT activity is an 
autocrine source of ROS and other free radicals, 
capable of promoting prooxidant reactions at the 
cellular surface and in the microenvironment [11]. 
High levels of GGT activity are often expressed in 
many human neoplasms, both primitive and 
metastatic (carcinomas of ovary, colon, liver; sarcoma; 
leukemias; melanoma; reviewed in [12]). We showed 
that GGT-expressing cancer cells can exploit this 
activity in order to oxidize extracellular AA and 
subsequently uptake the resulting DHA [13], similarly 
to what was described for activated neutrophils 
following the onset of respiratory burst [14]. 
Other factors involved in AA sensitivity 
A recent study has highighted the expression of 
GGT in gastric cancer as well, and proposed tumor 
GGT levels as a poor prognostic factor as it was 
associated with lymph node metastasis and 
progression through EMT, KRAS, SRC and PKCA 
pathways [15]. Interestingly, others demonstrated the 
involvement of Ras pathway in the oxidative 
stress-induced activation of GGT in colon carcinoma 
cells [16]. Also, a recent study showed that KRAS and 
BRAF mutants presented with an increased 
expression of GLUT1. These cells were more sensitive 
to ascorbate cytotoxicity, mediated through 
DHA-induced inhibition of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and NAD+ 
depletion, resulting in a decreased glycolytic flux [17]. 
Thus, a combination of GLUT1 and GGT expression, 
as well as KRAS mutation, could improve the 
identification of cancer patients with enhanced 
sensitivity to AA. As recently rewieved [18] and 
mentioned above, AA toxicity was also related to the 
intracellular levels of iron (the so-called labile iron 
pool, LIP), at least in glioblastoma and NSCLC cell 
lines [6]. Others showed that Ras (and c-Myc)- 
dependent pathways were also involved in the 
increase of LIP [19, 20].  
Actually, several factors may concur to modulate 
ascorbate citotoxicity, and the efficacy of potential 
biomarkers in predicting AA sensitivity likely 
depends on the individual cancer cell types 
considered. In melanoma cells, we found that 
increased GGT levels can induce a higher resistance 
against oxidative stress due to an increased activity of 
catalase. This phenomenon could in principle protect 
cancer cells from ascorbate-dependent (prooxidant) 
cytotoxic effects [21]. Indeed, it was reported that 
tumor levels of catalase activity could predict which 
cancers would respond to pharmacological AA [22]. 
In our melanoma model, increased catalase stability 
and activity – associated with increased p38 
phosphorylation – was interpreted as the result of a 
persistent, low-level oxidative stress induced by GGT 
expression [23]. Anyway, although 
GGT-overexpressing cells were resistant to oxidative 
stress, in our hands the prooxidant action of ascorbate 
might still be exploited in order to enhance the 
cytotoxicity of another prooxidant agent, arsenic 
trioxide [23]. Several recent studies focused on 
combination therapies aiming at overcoming the 
antioxidant resistance of tumors expressing high 
catalase activities, e.g.  [18, 22, 24]. In this perspective, 
the inhibition/modulation of GGT-dependent 
pathway(s) involved in the observed increase in 
catalase activity could be proposed as a further means 
for enhancing the therapeutic potential of ascorbate.  
Conclusions 
In the light of the data discussed above, it can be 
speculated that expression levels of GLUT1 and GGT – 
together with Ras mutation – could be jointly 
investigated, as the combination of high levels of 
these biomarkers might identify neoplasms with even 
higher sensitivity to treatments with pharmacological 





ascorbate. In particular, GGT expression appears to be 
associated with more aggressive forms, for which the 
identification of effective treatments would be of even 
higher value.  
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